$NXTC
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
Healthcare
Sector
Biotechnology
Industry
Michael S. Richman
CEO
43
Employees
$6.40
Current Price
$30.01M
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 1 | 1 | $62,897.07 | 12,333 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 1 | 3 | $86,795.67 | 17,019 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 1 | 6 | $140,486.99 | 27,870 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 2 months | Buys | 1 | 6 | $140,486.99 | 27,870 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 3 months | Buys | 1 | 6 | $140,486.99 | 27,870 | All Buys |
| Sells | 0 | 0 | - | - | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Nov 11, 2026 | ADAR1 Capital Management, LLC 10% Owner | Purchase | 12,333 | $5.10 | $62,897.07 | View Details |
| Nov 6, 2026 | ADAR1 Capital Management, LLC 10% Owner | Purchase | 3,662 | $5.10 | $18,676.20 | View Details |
| Nov 5, 2026 | ADAR1 Capital Management, LLC 10% Owner | Purchase | 1,024 | $5.10 | $5,222.40 | View Details |
| Oct 26, 2026 | ADAR1 Capital Management, LLC 10% Owner | Purchase | 1,672 | $5.03 | $8,417.52 | View Details |
| Oct 27, 2026 | ADAR1 Capital Management, LLC 10% Owner | Purchase | 3,553 | $5.10 | $18,103.60 | View Details |
| Oct 23, 2026 | ADAR1 Capital Management, LLC 10% Owner | Purchase | 5,626 | $4.83 | $27,170.20 | View Details |
14 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
EPS
Estimated-$0.90
ActualN/A
Revenue
EstimatedN/A
ActualN/A
EPS
Estimated-$0.90
Actual-$1.29
Miss
Revenue
EstimatedN/A
ActualN/A
EPS
Estimated-$0.90
ActualN/A
Revenue
EstimatedN/A
ActualN/A
1 more earnings records available โ create a free account to see 12 months of history
Related Activity
Cross-company insider connections and cluster buy signals
Insiders Also Active At
Insiders at this company also hold positions or have traded at these companies: